Viking Therapeutics Advances VK2735 Trials with Q4 2024 Financial Update
February 7, 2025 - 02:25
Viking Therapeutics has provided an update on its financial performance for the fourth quarter of 2024 while highlighting the progress of its oral VK2735 in Phase 2 clinical trials. The company reported significant advancements in its research and development efforts, particularly focusing on VK2735, a novel therapeutic candidate aimed at addressing metabolic disorders.
The Phase 2 trials are crucial for determining the efficacy and safety of VK2735, with results anticipated in the second half of 2025. This timeline positions Viking Therapeutics to potentially make substantial contributions to the treatment landscape for conditions such as obesity and type 2 diabetes. The company is optimistic about the ongoing trials and remains committed to delivering innovative solutions for patients.
In addition to the clinical advancements, Viking's financial results reflect a strategic approach to funding its research initiatives. The company continues to explore opportunities for growth and collaboration in the biotechnology sector, ensuring that it remains at the forefront of medical innovation.
MORE NEWS
July 6, 2026 - 17:52
COVID Tax Returns: Are you eligible to get them and what is the deadline to apply for them?Millions of Americans may still be owed money from COVID-era tax credits, but claiming those funds requires action before a looming deadline. The Internal Revenue Service has been notifying...
July 5, 2026 - 17:25
Campaign finance ruling could tighten ties between donors, parties and candidatesMADISON, Wis. - The U.S. Supreme Court this week removed federal limits on how much money national political party committees can spend in direct coordination with their candidates, a decision that...
July 5, 2026 - 00:20
1 Unstoppable Stock to Buy Before It Joins Google, Apple, Microsoft, and Nvidia in the $3 Trillion ClubTaiwan Semiconductor Manufacturing Company, better known as TSMC, is quietly positioning itself to join the most exclusive club in the stock market. Right now, only four companies have reached a...
July 4, 2026 - 02:50
Is Inter & Co, Inc. (INTR) A Good Stock To Buy Now?A bullish thesis on Inter & Co, Inc. recently appeared on the Emerging Value Substack, drawing attention to the stock`s potential. As of June 29th, shares of INTR were trading at $5.38, with a...